Abstract
Background: This study was performed to investigate clinical characteristics and outcome after gamma knife radiosurgery (GKS) in patients with incidental, symptomatic unruptured, or ruptured arteriovenous malformations (AVMs). Methods: A total of 491 patients with brain AVMs treated with GKS from June 2002 to September 2017 were retrospectively reviewed. All patients were classified into the incidental (n = 105), symptomatic unruptured (n = 216), or ruptured AVM (n = 170) groups. Results: The mean age at diagnosis of incidental, symptomatic unruptured, and ruptured AVMs was 40.3, 36.7, and 27.6 years, respectively. The mean nidus volume was 3.9, 5.7, and 2.4 cm3, respectively. Deep venous drainage was identified in 34, 54, and 76% patients, respectively. There were no significant differences in obliteration rates after GKS between the 3 groups (64.8, 61.1, and 65.9%, respectively) after a mean follow-up period of 60.5 months; however, patients with incidental AVM had a significantly lower post-GKS hemorrhage rate than patients with symptomatic unruptured or ruptured AVMs (annual hemorrhage rate of 1.07, 2.87, and 2.69%; p = 0.028 and p = 0.049, respectively). Conclusions: There is a significant difference in clinical and anatomical characteristics between incidental, symptomatic unruptured, and ruptured AVMs. The obliteration rate after GKS is not significantly different between the 3 groups. Meanwhile, an older age at diagnosis and lower hemorrhage rate after GKS in incidental AVMs suggest that they have a more indolent natural course with a lower life-long risk of hemorrhage.
References
1.
Fleetwood
IG
, Steinberg
GK
. Arteriovenous malformations
. Lancet
. 2002
;359
(9309
):863
–73
. 2.
Stapf
C
, Mast
H
, Sciacca
RR
, Choi
JH
, Khaw
AV
, Connolly
ES
, et al. Predictors of hemorrhage in patients with untreated brain arteriovenous malformation
. Neurology
. 2006
;66
(9
):1350
–5
. 3.
Al-Shahi
R
, Bhattacharya
JJ
, Currie
DG
, Papanastassiou
V
, Ritchie
V
, Roberts
RC
, et al. Scottish Intracranial Vascular Malformation Study (SIVMS): evaluation of methods, ICD-10 coding, and potential sources of bias in a prospective, population-based cohort
. Stroke
. 2003
;34
(5
):1156
–62
. 4.
Sure
U
, Battenberg
E
, Dempfle
A
, Tirakotai
W
, Bien
S
, Bertalanffy
H
. Hypoxia-inducible factor and vascular endothelial growth factor are expressed more frequently in embolized than in nonembolized cerebral arteriovenous malformations
. Neurosurgery
. 2004
;55
(3
):663
–70
; discussion 669–670
. 5.
Hernesniemi
JA
, Dashti
R
, Juvela
S
, Väärt
K
, Niemelä
M
, Laakso
A
. Natural history of brain arteriovenous malformations: a long-term follow-up study of risk of hemorrhage in 238 patients
. Neurosurgery
. 2008
;63
(5
):823
–31
; discussion 829–831
. 6.
Halim
AX
, Johnston
SC
, Singh
V
, McCulloch
CE
, Bennett
JP
, Achrol
AS
, et al. Longitudinal risk of intracranial hemorrhage in patients with arteriovenous malformation of the brain within a defined population
. Stroke
. 2004
;35
(7
):1697
–702
. 7.
Kim
H
, Sidney
S
, McCulloch
CE
, Poon
KY
, Singh
V
, Johnston
SC
, et al. Racial/Ethnic differences in longitudinal risk of intracranial hemorrhage in brain arteriovenous malformation patients
. Stroke
. 2007
;38
(9
):2430
–7
. 8.
da Costa
L
, Wallace
MC
, Ter Brugge
KG
, O’Kelly
C
, Willinsky
RA
, Tymianski
M
. The natural history and predictive features of hemorrhage from brain arteriovenous malformations
. Stroke
. 2009
;40
(1
):100
–5
. 9.
Yamada
S
, Takagi
Y
, Nozaki
K
, Kikuta
K
, Hashimoto
N
. Risk factors for subsequent hemorrhage in patients with cerebral arteriovenous malformations
. J Neurosurg
. 2007
;107
(5
):965
–72
. 10.
Ondra
SL
, Troupp
H
, George
ED
, Schwab
K
. The natural history of symptomatic arteriovenous malformations of the brain: a 24-year follow-up assessment
. J Neurosurg
. 1990
;73
(3
):387
–91
. 11.
Gross
BA
, Du
R
. Natural history of cerebral arteriovenous malformations: a meta-analysis
. J Neurosurg
. 2013
;118
(2
):437
–43
. 12.
Pollock
BE
, Flickinger
JC
, Lunsford
LD
, Bissonette
DJ
, Kondziolka
D
. Factors that predict the bleeding risk of cerebral arteriovenous malformations
. Stroke
. 1996
;27
(1
):1
–6
. 13.
Gross
BA
, Du
R
. Rate of re-bleeding of arteriovenous malformations in the first year after rupture
. J Clin Neurosci
. 2012
;19
(8
):1087
–8
. 14.
Ding
D
, Starke
RM
, Kano
H
, Mathieu
D
, Huang
P
, Kondziolka
D
, et al. Radiosurgery for cerebral arteriovenous malformations in a randomized trial of unruptured brain arteriovenous malformations (ARUBA)-eligible patients: a Multicenter Study
. Stroke
. 2016
;47
(2
):342
–9
. 15.
Yen
CP
, Ding
D
, Cheng
CH
, Starke
RM
, Shaffrey
M
, Sheehan
J
. Gamma Knife surgery for incidental cerebral arteriovenous malformations
. J Neurosurg
. 2014
;121
(5
):1015
–21
. 16.
Moon
K
, Levitt
MR
, Almefty
RO
, Nakaji
P
, Albuquerque
FC
, Zabramski
JM
, et al. Safety and efficacy of surgical resection of unruptured low-grade arteriovenous malformations from the modern decade
. Neurosurgery
. 2015
;77
(6
):948
–3
; discussion 952–943
. 17.
Bervini
D
, Morgan
MK
, Ritson
EA
, Heller
G
. Surgery for unruptured arteriovenous malformations of the brain is better than conservative management for selected cases: a prospective cohort study
. J Neurosurg
. 2014
;121
(4
):878
–90
. 18.
Ding
D
, Sheehan
JP
, Starke
RM
, Durst
CR
, Raper
DM
, Conger
JR
, et al. Embolization of cerebral arteriovenous malformations with silk suture particles prior to stereotactic radiosurgery
. J Clin Neurosci
. 2015
;22
(10
):1643
–9
. 19.
Ding
D
, Liu
KC
. Predictive capability of the spetzler-martin versus supplementary grading scale for microsurgical outcomes of cerebellar arteriovenous malformations
. J Cerebrovasc Endovasc Neurosurg
. 2013
;15
(4
):307
–10
. 20.
Lawton
MT
, Kim
H
, McCulloch
CE
, Mikhak
B
, Young
WL
. A supplementary grading scale for selecting patients with brain arteriovenous malformations for surgery
. Neurosurgery
. 2010
;66
(4
):702
–13
; discussion 713
. 21.
Stapf
C
, Mohr
JP
. Unruptured brain arteriovenous malformations should be treated conservatively: yes
. Stroke
. 2007
;38
(12
):3308
–9
. 22.
Starke
RM
, Sheehan
JP
, Ding
D
, Liu
KC
, Kondziolka
D
, Crowley
RW
, et al. Conservative management or intervention for unruptured brain arteriovenous malformations
. World Neurosurg
. 2014
;82
(5
):e668
–9
. 23.
Ding
D
, Xu
Z
, Yen
CP
, Starke
RM
, Sheehan
JP
. Radiosurgery for unruptured cerebral arteriovenous malformations in pediatric patients
. Acta Neurochir
. 2015
;157
(2
):281
–91
. 24.
Tonetti
DA
, Gross
BA
, Atcheson
KM
, Jankowitz
BT
, Kano
H
, Monaco
EA
, et al. The benefit of radiosurgery for ARUBA-eligible arteriovenous malformations: a practical analysis over an appropriate follow-up period
. J Neurosurg
. 2018
;128
(6
):1850
–4
. 25.
Hanakita
S
, Shin
M
, Koga
T
, Igaki
H
, Saito
N
. Risk reduction of cerebral stroke after stereotactic radiosurgery for small unruptured brain arteriovenous malformations
. Stroke
. 2016
;47
(5
):1247
–52
. 26.
Ding
D
, Starke
RM
, Kano
H
, Lee
JYK
, Mathieu
D
, Pierce
J
, et al. Radiosurgery for unruptured brain arteriovenous malformations: an International Multicenter Retrospective Cohort Study
. Neurosurgery
. 2017
;80
(6
):888
–98
. 27.
Spetzler
RF
, Martin
NA
. A proposed grading system for arteriovenous malformations
. J Neurosurg
. 1986
;65
(4
):476
–83
. 28.
Martin
D
, Austin
H
. An efficient program for computing conditional maximum likelihood estimates and exact confidence limits for a common odds ratio
. Epidemiology
. 1991
;2
(5
):359
–62
. 29.
Martin
DO
, Austin
H
. Exact estimates for a rate ratio
. Epidemiology
. 1996
;7
(1
):29
–33
. .30.
Armitage
P
, Berry
G
, Matthews
JNS
. Statistical methods in medical research
. Malden, MA
: Blackwell Science
; 2010
.31.
Mohr
JP
, Parides
MK
, Stapf
C
, Moquete
E
, Moy
CS
, Overbey
JR
, et al. Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA): a multicentre, non-blinded, randomised trial
. Lancet
. 2014
;383
(9917
):614
–21
. 32.
Koga
T
, Shin
M
, Terahara
A
, Saito
N
. Outcomes of radiosurgery for brainstem arteriovenous malformations
. Neurosurgery
. 2011
;69
(1
):45
–2
; discussion 51–42
. 33.
Maruyama
K
, Kondziolka
D
, Niranjan
A
, Flickinger
JC
, Lunsford
LD
. Stereotactic radiosurgery for brainstem arteriovenous malformations: factors affecting outcome
. J Neurosurg
. 2004
;100
(3
):407
–13
. 34.
Pollock
BE
, Gorman
DA
, Brown
PD
. Radiosurgery for arteriovenous malformations of the basal ganglia, thalamus, and brainstem
. J Neurosurg
. 2004
;100
(2
):210
–4
. 35.
Al-Shahi Salman
R
, White
PM
, Counsell
CE
, du Plessis
J
, van Beijnum
J
, Josephson
CB
, et al. Outcome after conservative management or intervention for unruptured brain arteriovenous malformations
. JAMA
. 2014
;311
(16
):1661
–9
. 36.
Nozaki
K
, Hashimoto
N
, Kikuta
K
, Takagi
Y
, Kikuchi
H
. Surgical applications to arteriovenous malformations involving the brainstem
. Neurosurgery
. 2006
;58
(4 Suppl 2
):ONS-270–8
; discussion ONS-278–9
. 37.
Kim
H
, Al-Shahi Salman
R
, McCulloch
CE
, Stapf
C
, Young
WL
; MARS Coinvestigators
. Untreated brain arteriovenous malformation: patient-level meta-analysis of hemorrhage predictors
. Neurology
. 2014
;83
(7
):590
–7
. © 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
